Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure [Seeking Alpha]
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: Seeking Alpha
ARCT is priced as a busted biotech with optionality; cash runway extends to 2028, but clinical and regulatory risks remain significant. ARCT-032's 12-week trial and ARCT-810's FDA alignment are key re-rating catalysts; both programs face pivotal data and regulatory endpoints. Market skepticism is reflected in ARCT's sub-1 P/BV and low P/S multiples, but positive trial outcomes could drive rapid multiple expansion. Monty Rakusen/DigitalVision via Getty Images I wrote about Arcturus Therapeutics ( ARCT before . At the time, the company was mostly seen as a Covid vaccine play. Well, the company is no longer a Covid story. Yes, the company still has exposure to its This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ARCT over the next 72 hours. I wrote t
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating [Yahoo! Finance]Yahoo! Finance
- Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics (NASDAQ:ARCT) was upgraded by analysts at Roth Mkm to a "strong-buy" rating.MarketBeat
- Arcturus Therapeutics (NASDAQ:ARCT) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Arcturus Therapeutics (NASDAQ:ARCT) is now covered by analysts at Roth Mkm. They set a "buy" rating on the stock.MarketBeat
ARCT
Earnings
- 11/10/25 - Beat
ARCT
Sec Filings
- 2/3/26 - Form SCHEDULE
- 1/8/26 - Form SCHEDULE
- 12/30/25 - Form S-3
- ARCT's page on the SEC website